An interview with Bernardo Perez-Ramirez, Sanofi, speaker at the 9th Annual Proteins & Antibodies Congress, 18-19 April 2016, London, UK
Posted: 13 January 2016 | Oxford Global | No comments yet
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations…
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations about the drivers behind the growth of the biologics industry. Bernardo will be speaking at the meeting next April on the topic of ‘Early Preformulation Research: Device Ability Work Flows in Therapeutic Proteins’.
We asked Bernardo his thoughts about the most exciting developments for the biologics industry over the next couple of years:
“There are several challenges facing the biopharmaceutical industry nowadays. Regulatory requirements are changing; companies are global, where sites for development scale up and manufacturing may be in different continents, therefore requiring a close coordination of operations… Another exciting area is the development of gene therapy approaches for some unmet medical needs as well as the identification of biocompatible materials for sustained release of active drugs.”
When asked about the technologies poised to have an impact in the proteins and antibodies field, Bernardo highlighted the role of formulation technologies:
“A formulation technology that could decrease viscosity could be very valuable as well as the understanding of structural fixtures in the molecules that may modulate viscosity and other rheological properties. This continues to be a very exciting area of investigation.”
Click here to read the full interview with Bernardo.
On Day 1 of the 9th Annual Proteins and Antibodies Congress Bernardo will be speaking about ‘Early Preformulation Research: Device Ability Work Flows In Therapeutic Proteins’
9th Annual Proteins & Antibodies Congress
This is the meeting place for over 400 senior-level biologics experts and will feature the following speakers and topics:
- Haruki Hasegawa, Principal Scientist at Amgen will discuss Predicting Undesirable Solution Properties Of Mab Clones From Their Overexpression-Induced Cell Phenotypes
- Ronald Smulders, Executive Director, Analytical Development and Validation, MSD will speak about analytical strategies in a breakthrough mAb program
- Steve Hall, Director of Pfizer Regulatory Strategy, Pfizer Worldwide Research and Development will share his experience of clinical trials with antibody drug conjugates
Across the two days there will be over 40 case studies, presentations and panel discussions focused on the key issues in antibody discovery, protein expression, purification challenges and therapeutic antibodies.
Download the agenda here to view the full line up of speakers and their presentations. Registration
Contact Danielle Dalby today on [email protected] or call +44(0)1865 248455 to secure your place. Limited places now available.